HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study

Abstract

Background

Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conficting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals.

Methods

The prospective observational database of the D:A:D collaboration of 11 cohorts of HIV-infected individuals, including 212 clinics in Europe, the United States and Australia was used. Multivariate Poisson regression was used to assess the effect of HCV or HBV infection on the development of myocardial infarction after adjustment for potential confounders, including cardiovascular risk factors, diabetes mellitus and exposure to antiretroviral therapy.

Results

Of 33,347 individuals, 517 developed a myocardial infarction over 157,912 person-years, with an event rate of 3.3 events/1,000 person-years (95% confidence interval [CI] 3.0–3.6). Event rates (95% CIs) per 1,000 person-years in those who were HCV- seronegative and HCV-seropositive were 3.3 (3.0–3.7) and 2.7 (2.2–3.3), respectively, and for those who were HBV-seronegative, had inactive infection or had active infection were 3.2 (2.8–3.5), 4.2 (3.1–5.2) and 2.8 (1.8–3.9), respectively. After adjustment, there was no association between HCV seropositivity (rate ratio 0.86 [95% CI 0.62–1.19]), inactive HBV infection (rate ratio 1.07 [95% CI 0.79–1.43]) or active HBV infection (rate ratio 0.78 [95% CI 0.52–1.15]) and the development of myocardial infarction.

Conclusions

We found no association between HBV or HCV coinfection and the development of myocardial infarction among HIV-infected individuals.

References

Bedimo

, Ghurani

, Nsuami

Lipid abnormalities in HIV/hepatitis C virus-coinfected patients.

HIV Med 2006; 7: 530–536.

Collazos

, Mayo

, Ibarra

Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection.

AIDS 2003; 17: 927–929.

Floris-Moore

, Howard

A.A.

, Lo

Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men.

AIDS Patient Care STDS 2007; 21: 479–491.

Dai

C.Y.

, Chuang

W.L.

, Ho

C.K.

Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study.

J Hepatol 2008; 49: 9–16.

Reingold

, Wanke

, Kotler

Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study.

J Acquir Immune Defic Syndr 2008; 48: 142–148.

Libby

, Egan

, Skarlatos

Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research.

Circulation 1997; 96: 4095–4103.

Fabricant

C.G.

, Fabricant

, Litrenta

M.M.

Virus-induced atherosclerosis.

J Exp Med 1978; 148: 335–340.

Muhlestein

J.B.

, Anderson

J.L.

, Hammond

E.H.

Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model.

Circulation 1998; 97: 633–636.

Mayr

, Kiechl

, Willeit

Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis.

Circulation 2000; 102: 833–839.

10.

Zhu

, Nieto

F.J.

, Horne

B.D.

Prospective study of pathogen burden and risk of myocardial infarction or death.

Circulation 2001; 103: 45–51.

11.

Zhu

, Quyyumi

A.A.

, Norman

J.E.

The possible role of hepatitis A virus in the pathogenesis of atherosclerosis.

J Infect Dis 2000; 182: 1583–1587.

12.

Danesh

, Collins

, Peto

Chronic infections and coronary heart disease: is there a link?

Lancet 1997; 350: 430–436.

13.

O'Connor

, Taylor

, Campbell

L.A.

Potential infectious etiologies of atherosclerosis: a multifactorial perspective.

Emerg Infect Dis 2001; 7: 780–788.

14.

Ludewig

, Freigang

, Jaggi

Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model.

Proc Natl Acad Sci U S A 2000; 97: 12752–12757.

15.

Nicoletti

, Kaveri

, Caligiuri

Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.

J Clin Invest 1998; 102: 910–918.

16.

The DAD Study Group.

Class of antiretroviral drugs and the risk of myocardial infarction.

N Engl J Med 2007; 356: 1723–1735.

17.

The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group.

Combination antiretroviral therapy and the risk of myocardial infarction.

N Engl J Med 2003; 349: 1993–2003.

18.

Friis-Moller

, Weber

, Reiss

Cardiovascular disease risk factors in HIV patients –association with antiretroviral therapy. Results from the DAD study.

AIDS 2003; 17: 1179–1193.

19.

D:A:D Study Group.

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

Lancet 2008; 371: 1417–1426.

20.

Ledergerber

, Furrer

, Rickenbach

Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study.

Clin Infect Dis 2007; 45: 111–119.

21.

De Wit

, Sabin

, Weber

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Diabetes Care 2008; 31: 1224–1229.

22.

The SMART/INSIGHT and DAD Study Groups.

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.

AIDS 2008; 22: F17–F24.

23.

Hsue

P.Y.

, Hunt

P.W.

, Wu

Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients.

AIDS 2009; 23: 2021–2027.

24.

Hsue

P.Y.

, Hunt

P.W.

, Schnell

Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis.

AIDS 2009; 23: 1059–1067.

25.

de Larranaga

G.F.

, Wingeyer

S.D.

, Puga

L.M.

Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV–HCV-coinfected patients under highly active antiretroviral treatment.

Eur J Clin Microbiol Infect Dis 2006; 25: 98–103.

26.

The Data Collection on Adverse Events of Anti-HIV Drugs Study Group.

Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Arch Intern Med 2006; 166: 1632–1641.

27.

Tunstall-Pedoe

, Kuulasmaa

, Amouyel

Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.

Circulation 1994; 90: 583–612.

28.

Sterne

J.A.

, White

I.R.

, Carlin

J.B.

Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls.

BMJ 2009; 338: b2393.

29.

Hernan

M.A.

, Brumback

, Robins

J.M.

Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

Epidemiology 2000; 11: 561–570.

30.

Weber

, Sabin

C.A.

, Reiss

Hepatitis virus co-infections and risk of diabetes mellitus and myocardial infarction in HIV-infected persons: The D:A:D Study. 15th Conference on Retroviruses and Opportunistic Infections. 3–6 February 2008, Boston, MA, USA. Abstract 1082.

31.

Ishizaka

, Ishizaka

, Takahashi

Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening.

Lancet 2002; 359: 133–135.

32.

Ishizaka

, Ishizaka

, Takahashi

Association between hepatitis C virus core protein and carotid atherosclerosis.

Circ J 2003; 67: 26–30.

33.

Fukui

, Kitagawa

, Nakamura

Hepatitis C virus and atherosclerosis in patients with type 2 diabetes.

JAMA 2003; 289: 1245–1246.

34.

Vassalle

, Masini

, Bianchi

Evidence for association between hepatitis C virus seropositivity and coronary artery disease.

Heart 2004; 90: 565–566.

35.

Tien

P.C.

, Schneider

M.F.

, Cole

S.R.

Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study.

AIDS 2009; 23: 1781–1784.

36.

Arcari

C.M.

, Nelson

K.E.

, Netski

D.M.

No association between hepatitis C virus seropositivity and acute myocardial infarction.

Clin Infect Dis 2006; 43: e53–e56.

37.

Völzke

, Schwahn

, Wolff

Hepatitis B and C virus infection and the risk of atherosclerosis in a general population.

Atherosclerosis 2004; 174: 99–103.

38.

Butt

A.A.

, Xiaoqiang

, Budoff

Hepatitis C virus infection and the risk of coronary disease.

Clin Infect Dis 2009; 49: 225–232.

39.

Freiberg

M.S.

, Cheng

D.M.

, Kraemer

K.L.

The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals.

AIDS 2007; 21: 193–197.

40.

Bedimo

, Westfall

A.O.

, Mugavero

, Drechsler

, Khanna

, Saag

Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients.

HIV Med 2010; 11: 462–468.

41.

Ishizaka

, Ishizaka

, Takahashi

Increased prevalence of carotid atherosclerosis in hepatitis B virus carriers.

Circulation 2002; 105: 1028–1030.

42.

Kiechl

, Egger

, Mayr

Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study.

Circulation 2001; 103: 1064–1070.

43.

Momiyama

, Ohmori

, Kato

Lack of any association between persistent hepatitis B or C virus infection and coronary artery disease.

Atherosclerosis 2005; 181: 211–213.

44.

Tong

D.Y.

, Wang

X.H.

, Xu

C.F.

Hepatitis B virus infection and coronary atherosclerosis: results from a population with relatively high prevalence of hepatitis B virus.

World J Gastroenterol 2005; 11: 1292–1296.

45.

Sung

, Song

Y.M.

, Choi

Y.H.

Hepatitis B virus seropositivity and the risk of stroke and myocardial infarction.

Stroke 2007; 38: 1436–1441.

46.

Petty

G.W.

, Duffy

Houston J, 3rd. Cerebral ischemia in patients with hepatitis C virus infection and mixed cryoglobulinemia.

Mayo Clin Proc 1996; 71: 671–678.

47.

Delluc

, Saadoun

, Ghillani-Dalbin

Cryofibrinogen in patients with hepatitis C virus infection.

Am J Med 2008; 121: 624–631.

48.

Capra

, De Maria

, Lunardi

Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: a prognostic marker for responses to interferon treatment.

J Infect Dis 2000; 181: 425–431.

49.

Cacoub

, Ghillani

, Revelen

Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia.

J Hepatol 1999; 31: 598–603.

50.

Sumida

, Nakashima

, Yoh

Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection.

J Hepatol 2000; 33: 616–622.

51.

Okuda

, Li

, Beard

M.R.

Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein.

Gastroenterology 2002; 122: 366–375.

52.

, Prow

, Lemon

S.M.

Cellular response to conditional expression of hepatitis C virus core protein in Huh7 cultured human hepatoma cells.

Hepatology 2002; 35: 1237–1246.

53.

Sansonno

, Tucci

F.A.

, Troiani

Increased serum levels of the chemokine CXCL13 and upregulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis.

Blood 2008; 112: 1620–1627.

54.

Guillevin

, Mahr

, Callard

Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients.

Medicine (Baltimore) 2005; 84: 313–322.

55.

Agnello

, Abel

Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia.

Arthritis Rheum 1997; 40: 2007–2015.

56.

Mason

, Theal

, Bain

Hepatitis B virus replication in damaged endothelial tissues of patients with extrahepatic disease.

Am J Gastroenterol 2005; 100: 972–976.

57.

Meade

T.W.

, Stirling

, Thompson

S.G.

Carriers of hepatitis B surface antigen: possible association between low levels of clotting factors and protection against ischaemic heart disease.

Thromb Res 1987; 45: 709–713.

58.

Marchesini

, Ronchi

, Forlani

Cardiovascular disease in cirrhosis – a point-prevalence study in relation to glucose tolerance.

Am J Gastroenterol 1999; 94: 655–662.